820 related articles for article (PubMed ID: 29875097)
1. Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model.
Wu W; Jordan S; Becker MO; Dobrota R; Maurer B; Fretheim H; Ye S; Siegert E; Allanore Y; Hoffmann-Vold AM; Distler O
Ann Rheum Dis; 2018 Sep; 77(9):1326-1332. PubMed ID: 29875097
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis.
Hoffmann-Vold AM; Aaløkken TM; Lund MB; Garen T; Midtvedt Ø; Brunborg C; Gran JT; Molberg Ø
Arthritis Rheumatol; 2015 May; 67(8):2205-12. PubMed ID: 25916462
[TBL] [Abstract][Full Text] [Related]
3. Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease.
Suliman YA; Dobrota R; Huscher D; Nguyen-Kim TD; Maurer B; Jordan S; Speich R; Frauenfelder T; Distler O
Arthritis Rheumatol; 2015 Dec; 67(12):3256-61. PubMed ID: 26316389
[TBL] [Abstract][Full Text] [Related]
4. Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis.
Showalter K; Hoffmann A; Rouleau G; Aaby D; Lee J; Richardson C; Dematte J; Agrawal R; Chang RW; Hinchcliff M
J Rheumatol; 2018 Nov; 45(11):1572-1576. PubMed ID: 30275265
[TBL] [Abstract][Full Text] [Related]
5. Predicting Mortality in Systemic Sclerosis-Associated Interstitial Lung Disease Using Risk Prediction Models Derived From Idiopathic Pulmonary Fibrosis.
Ryerson CJ; O'Connor D; Dunne JV; Schooley F; Hague CJ; Murphy D; Leipsic J; Wilcox PG
Chest; 2015 Nov; 148(5):1268-1275. PubMed ID: 25996795
[TBL] [Abstract][Full Text] [Related]
6. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
[TBL] [Abstract][Full Text] [Related]
7. Performance capacity evaluated using the 6-minute walk test: 5-year results in patients with diffuse systemic sclerosis and initial interstitial lung disease.
Rizzi M; Sarzi-Puttini P; Airoldi A; Antivalle M; Battellino M; Atzeni F
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S142-7. PubMed ID: 26339893
[TBL] [Abstract][Full Text] [Related]
8. Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis.
Tashkin DP; Volkmann ER; Tseng CH; Kim HJ; Goldin J; Clements P; Furst D; Khanna D; Kleerup E; Roth MD; Elashoff R
Ann Rheum Dis; 2016 Feb; 75(2):374-81. PubMed ID: 25452309
[TBL] [Abstract][Full Text] [Related]
9. Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease.
Moore OA; Proudman SM; Goh N; Corte TJ; Rouse H; Hennessy O; Morrisroe K; Thakkar V; Sahhar J; Roddy J; Youssef P; Gabbay E; Nash P; Zochling J; Stevens W; Nikpour M
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S111-6. PubMed ID: 26243401
[TBL] [Abstract][Full Text] [Related]
10. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
[TBL] [Abstract][Full Text] [Related]
11. Does Systemic Sclerosis-associated Interstitial Lung Disease Burn Out? Specific Phenotypes of Disease Progression.
Guler SA; Winstone TA; Murphy D; Hague C; Soon J; Sulaiman N; Li KH; Dunne J; Wilcox PG; Ryerson CJ
Ann Am Thorac Soc; 2018 Dec; 15(12):1427-1433. PubMed ID: 30188737
[TBL] [Abstract][Full Text] [Related]
12. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V
Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515
[TBL] [Abstract][Full Text] [Related]
13. Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis.
Hax V; Bredemeier M; Didonet Moro AL; Pavan TR; Vieira MV; Pitrez EH; da Silva Chakr RM; Xavier RM
Semin Arthritis Rheum; 2017 Oct; 47(2):228-234. PubMed ID: 28454677
[TBL] [Abstract][Full Text] [Related]
14. Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis.
Goh NS; Hoyles RK; Denton CP; Hansell DM; Renzoni EA; Maher TM; Nicholson AG; Wells AU
Arthritis Rheumatol; 2017 Aug; 69(8):1670-1678. PubMed ID: 28426895
[TBL] [Abstract][Full Text] [Related]
15. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.
Adler S; Huscher D; Siegert E; Allanore Y; Czirják L; DelGaldo F; Denton CP; Distler O; Frerix M; Matucci-Cerinic M; Mueller-Ladner U; Tarner IH; Valentini G; Walker UA; Villiger PM; Riemekasten G;
Arthritis Res Ther; 2018 Jan; 20(1):17. PubMed ID: 29382380
[TBL] [Abstract][Full Text] [Related]
16. Combined Pulmonary Fibrosis and Emphysema in Scleroderma-Related Lung Disease Has a Major Confounding Effect on Lung Physiology and Screening for Pulmonary Hypertension.
Antoniou KM; Margaritopoulos GA; Goh NS; Karagiannis K; Desai SR; Nicholson AG; Siafakas NM; Coghlan JG; Denton CP; Hansell DM; Wells AU
Arthritis Rheumatol; 2016 Apr; 68(4):1004-12. PubMed ID: 26636545
[TBL] [Abstract][Full Text] [Related]
17. Ventilation distribution as a contributor to the functional exercise capacity in patients with systemic sclerosis-associated interstitial lung disease without pulmonary hypertension.
Andrade FM; Oliveira AD; Lopes AJ
Braz J Med Biol Res; 2019; 52(8):e8513. PubMed ID: 31365695
[TBL] [Abstract][Full Text] [Related]
18. Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy?
Yamakawa H; Takemura T; Iwasawa T; Yamanaka Y; Ikeda S; Sekine A; Kitamura H; Baba T; Iso S; Okudela K; Kuwano K; Ogura T
BMC Pulm Med; 2018 Jan; 18(1):25. PubMed ID: 29382307
[TBL] [Abstract][Full Text] [Related]
19. Chest wall muscle atrophy as a contributory factor for forced vital capacity decline in systemic sclerosis-associated interstitial lung disease.
Nawata T; Shirai Y; Suzuki M; Kuwana M
Rheumatology (Oxford); 2021 Jan; 60(1):250-255. PubMed ID: 32699895
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease.
Caron M; Hoa S; Hudson M; Schwartzman K; Steele R
Eur Respir Rev; 2018 Jun; 27(148):. PubMed ID: 29769294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
